INVISION supports Cygna Labs in the acquisition of Nokia’s DDI business unit

Cygna Labs, a highly specialized software developer focused on network, compliance and cloud security solutions, has entered into a definitive agreement to acquire VitalQIP, a global DDI software provider from Nokia Solutions & Network Oy (“Nokia”). Cygna Labs was supported by the private equity company INVISION, which has a majority stake in the Miami-based company. The acquisition comprises Nokia’s VitalQIP product, related intellectual property as well as its customers and associated personnel.

Cygna Labs is a leading software developer in the fields of network, cloud and security and one of the top three global DDI vendors. Many Fortune 100 customers rely on Cygna Labs’ DDI products and services, in addition to its industry-leading security and compliance solutions, to detect and proactively mitigate data security threats, pass compliance audits, and increase the productivity of their IT departments.

Cygna Labs’ will ensure VitalQIP customers not only receive extensive ongoing maintenance and support services, including global 24×7 support but will also be able to take advantage of Cygna Labs’ expertise and innovation. The product will remain a standalone product line and has already been incorporated into Cygna Labs’ portfolio of managed service offerings.

Alexander Häcker, CEO of Cygna Labs Group, notes: “Cygna Labs continues to support large-scale enterprise customers that rely on our DDI products and services. This acquisition will expand our offering to include VitalQIP’s industry-proven open and scalable DDI solutions and will be offered side-by-side with our existing DDI offerings.

Adding Nokia’s leading DDI product enhances our intellectual property and will place Cygna Labs in the number two market share position”, adds Christian Ehrenthal, CEO of Cygna Labs. “From a business perspective, this acquisition enhances the Cygna Labs product portfolio, brings additional Fortune 100 companies to our client roster, and increases opportunities for Cygna Labs to expand our combined global market presence.



Since its foundation in 1997, INVISION has successfully developed into one of Europe’s leading investors for succession solutions and growth financing for medium-sized companies. During this time, INVISION has invested more than EUR 1 billion in over 60 companies and achieved sustainable valuation creation. INVISION acts as an entrepreneurial partner to entrepreneurs and management teams. As part of its growth levers, INVISION seeks to internationalize businesses, introduce new products and services as well as catalyze the internal digitalization process.

Further information can be found on www.invision.ch


Media contacts

Grünstrasse 23
40212 Düsseldorf / Germany
Tel. +49 211 936 727 50 E-Mail: info@invision.ch

Contact Us


    Invision AG
    Grafenaustrasse 7
    6300 Zug

    T +41 41 729 01 01
    F +41 41 729 01 00
    E info(at)invision.ch


    Invision Beteiligungsberatung GmbH
    Grünstraße 23
    40212 Düsseldorf

    T +49 211 936 727 50
    F +49 211 936 727 59
    T info(at)invision.ch